Company patents
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. demonstrates a clear focus on core pharmaceutical innovation, with Heterocyclic Compounds comprising a dominant 87.8% of its portfolio. While categories like Pharmaceutical Preparations and Therapeutic Activity (Pharma) saw strong growth in 2024 (YoY +41.7% and +36.4% respectively), the significant year-over-year declines across all categories in 2025 and so far in 2026, particularly in Acyclic / Carbocyclic Compounds and General Organic Chemistry Methods (both -100.0% in 2026), suggest a shifting or contracting patenting strategy in these areas.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
98 US filings (since 2023) · 6 categories · 5 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Patents
Showing 1-2 of 2
API Solid Form Engineering